MSF: Gilead Access Initiative ‘Nothing More Than A Public Relations Stunt’
Executive Summary
Gilead has failed to deliver on promises to make its liposomal amphotericin B (L-AmB) accessible to patients in developing countries, says Médecins Sans Frontières.